Prognostic Impact of ALDH1 Expression in Transitional Cell Carcinoma of the Renal Pelvis

To investigate the clinical significance of aldehyde dehydrogenase 1 (ALDH1) expression in the assessment of the pathological outcomes and prognosis of carcinoma of the renal pelvis through examination of ALDH1 expression in pathological specimens.

A total of 114 patients with carcinoma of the renal pelvis who underwent radical nephroureterectomy at the First Hospital of Peking University between September 2004 and August 2007 with continuity in data were included in this study. The expression of ALDH1 was examined in pathological specimens via immunohistochemistry, and was statistically analyzed in combination with corresponding clinical and pathological information.

The pathological specimens from 37 patients (32. 5%) exhibited positive ALDH1 expression, showing correlation with T stage (p=0. 001) and G grade (p=0. 010), as well as lymphatic and vascular infiltration (p=0. 003), but these specimens did not correlate with tumor multi-focality (p=0. 398). The univariate analysis showed that tumor grade (p=0. 001) and ALDH1 positive expression (p

The cancer stem-like cell marker ALDH1 can be used as a predictive factor for adverse pathological outcomes and prognosis in transitional cell carcinoma. of the renal pelvis. Cancer stem cell theory plays an important role in the clinical study of transitional cell carcinoma of the upper urinary tract.

Anticancer research. 2015 Sep [Epub]

Jia Liu, Jie Jin, Yong Yang, Wenke Han, Wei Yu, Chen Shen, Ning Zhang, Peng DU, Qiang Zhao, Shuo Wang, Xingxing Tang

Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital, Beijing, P. R. China. , Department of Urology, First Hospital of Peking University Peking University, Beijing, P. R. China. Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital, Beijing, P. R. China  , Department of Urology, First Hospital of Peking University Peking University, Beijing, P. R. China. , Department of Urology, First Hospital of Peking University Peking University, Beijing, P. R. China. , Department of Urology, First Hospital of Peking University Peking University, Beijing, P. R. China. , Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital, Beijing, P. R. China. , Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital, Beijing, P. R. China. , Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital, Beijing, P. R. China. , Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital, Beijing, P. R. China. , Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital, Beijing, P. R. China.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe